CD274 and small cell lung carcinoma: A large number of studies have confirmed that PD-1/PD-L1 inhibitors can benefit ES-SCLC patients in terms of survival (Ready et al. 2019; Chung et al. 2020; Horn et al. 2018; Paz-Ares et al. 2019).